Anti-Human MSLN Monoclonal Antibody (1A585) from ProteoGenix; catalogue ARO-A23350; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-Human MSLN Monoclonal Antibody (1A585) is a highly specific and reliable tool for targeting mesothelin (MSLN) in human cells. This monoclonal antibody is produced using advanced technology and has been extensively tested to ensure its high quality and consistency.
MSLN is a glycosylphosphatidylinositol-anchored cell surface glycoprotein that is overexpressed in various types of cancer, including mesothelioma, ovarian cancer, and pancreatic cancer. It plays a critical role in cancer progression and is considered a promising target for cancer therapy.
The Anti-Human MSLN Monoclonal Antibody (1A585) is specifically designed for use in various applications, including Western blotting, immunohistochemistry, and flow cytometry. It has been validated for use in human samples and has shown high sensitivity and specificity in detecting MSLN expression in cancer cells.
This antibody has been successfully used in a variety of experimental studies to investigate the role of MSLN in cancer. It has been used to study the expression of MSLN in different cancer cell lines and tissues, as well as in patient samples. It has also been used in functional studies to understand the role of MSLN in cancer cell proliferation, migration, and invasion.
With its high specificity and sensitivity, the Anti-Human MSLN Monoclonal Antibody (1A585) is an essential tool for researchers studying MSLN and its potential as a therapeutic target in cancer. Its reliable performance and consistent results make it a valuable addition to any research project.
In conclusion, the Anti-Human MSLN Monoclonal Antibody (1A585) is a highly specific and reliable tool for targeting MSLN in human cells. Its advanced technology, extensive testing, and validated applications make it an essential choice for researchers studying the role of MSLN in cancer. Add it to your research arsenal today and unlock the potential of MSLN as a therapeutic target.
ProteoGenix catalogue number ARO-A23350. For research use only.
Target: Mesothelin, CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, Megakaryocyte-potentiating factor, MPF, Mesothelin cleaved form, MSLN; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
